Sponsor hub
Daiichi Sankyo clinical trial failures
Review 31 stopped clinical trials from Daiichi Sankyo, including disease areas, phases, and classified stop reasons.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 5 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OPERATIONAL
- 16
- OTHER/UNKNOWN
- 10
- EFFICACY/FUTILITY
- 4
- SAFETY
- 1
Notable sponsors
- Daiichi Sankyo
- 31
Related phases
- Phase I
- 16
- Phase II
- 12
- Phase III
- 3
Crawlable stopped-trial records
Open ExploreShowing up to 31 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase I Netherton Syndrome trial by Daiichi Sankyo. Stop reason: OPERATIONAL.
The study was terminated based on a business decision by the Sponsor.
Phase I Advanced Cancer trial by Daiichi Sankyo. Stop reason: OTHER/UNKNOWN.
It was Daiichi Sankyo, Inc.'s decision to discontinue further internal development of DS-9606a
Phase II Breast Cancer trial by Daiichi Sankyo. Stop reason: OTHER/UNKNOWN.
The last participant was transitioned to alternative study.
Phase II Non-Small Cell Lung Cancer trial by Daiichi Sankyo. Stop reason: OTHER/UNKNOWN.
Last participant transitioned to alternative study.
Phase II Metastatic Colorectal Cancer trial by Daiichi Sankyo. Stop reason: EFFICACY/FUTILITY.
Study was terminated early given the Interim Analysis for Part 1 (signal finding) did not meet pre-specified criteria and will not proceed to Part 2. Sponsor will proceed closing the study.
Phase I Gastrointestinal Stromal Tumors trial by Daiichi Sankyo. Stop reason: OPERATIONAL.
The study was terminated due to a business decision.
Phase I Leukemia, Myeloid, Acute trial by Daiichi Sankyo. Stop reason: OPERATIONAL.
This study was terminated due to slow accrual.
Phase I Acute Myeloid Leukemia trial by Daiichi Sankyo. Stop reason: OPERATIONAL.
This study was terminated based on a business decision by the Sponsor.
Phase I Non-small Cell Lung Cancer (NSCLC) trial by Daiichi Sankyo. Stop reason: OPERATIONAL.
This study was terminated based on a business decision by the Sponsor.
Phase I Acute Myelogenous Leukemia trial by Daiichi Sankyo. Stop reason: OPERATIONAL.
This study was terminated based on a business decision by the Sponsor.
Phase I Solid Tumors trial by Daiichi Sankyo. Stop reason: OPERATIONAL.
The trial was terminated as per Sponsor decision.
Phase III Type 2 Diabetes Mellitus trial by Daiichi Sankyo. Stop reason: OTHER/UNKNOWN.
DSPD focusing on Study 301 to confirm the clinical profile before proceeding. Daiichi Sankyo Pharma Development terminated this study on 23 Apr 2008 because of changes in the clinical development plan with 94 of 2600 planned, randomized participants.
Phase II Non-CNS Germ Cell Tumors (Seminomas and Nonseminomas) trial by Daiichi Sankyo. Stop reason: EFFICACY/FUTILITY.
The study was terminated early for futility according to the stopping rule of the Simon 2-stage design.
Phase III Non Squamous, Non-small-cell Lung Cancer trial by Daiichi Sankyo. Stop reason: EFFICACY/FUTILITY.
Sponsor decision due to the protocol-defined stopping boundary for futility was met based on the interim OS data.
Phase II Colorectal Cancer trial by Daiichi Sankyo. Stop reason: OPERATIONAL.
Due to changes to the standard of care within the proposed market for CS-7017.
Phase I Anaplastic Thyroid Cancer trial by Daiichi Sankyo. Stop reason: OPERATIONAL.
Due to low enrollment, no participant had a dose limiting toxicity, therefore a maximum tolerated dose could not be established
Phase I V600-mutated BRAF Unresectable Melanoma trial by Daiichi Sankyo. Stop reason: EFFICACY/FUTILITY.
No activity was observed. BRAFi-naïve participants should have received triple combination treatment (including MEK inhibitor). Continuation was not justified.
Phase I Melanoma trial by Daiichi Sankyo. Stop reason: OTHER/UNKNOWN.
Terminated early for insufficient evidence of clinical efficacy
Phase II Prostate Cancer trial by Daiichi Sankyo. Stop reason: OPERATIONAL.
Business decision.
Phase II Recurrent Glioblastoma trial by Daiichi Sankyo. Stop reason: OPERATIONAL.
Business Decision
Phase I Colorectal Neoplasm trial by Daiichi Sankyo. Stop reason: OPERATIONAL.
Business Decision
Phase II Head and Neck Neoplasms trial by Daiichi Sankyo. Stop reason: OPERATIONAL.
Trial was terminated by sponsor due to lack of efficacy.
Phase II Pulmonary Embolism trial by Daiichi Sankyo. Stop reason: OTHER/UNKNOWN.
Product development cancelled.
Phase I Healthy trial by Daiichi Sankyo. Stop reason: SAFETY.
Safety concerns
Phase I Advanced Solid Tumors trial by Daiichi Sankyo. Stop reason: OPERATIONAL.
Program discontinued for business reasons (not safety).
Phase III Lung Cancer trial by Daiichi Sankyo. Stop reason: OTHER/UNKNOWN.
Pre-defined criteria for continuation were not reached
Phase I Metastatic Breast Cancer trial by Daiichi Sankyo. Stop reason: OPERATIONAL.
Improved, different standard of care caused business decision to terminate
Phase II Neuropathic Pain trial by Daiichi Sankyo. Stop reason: OTHER/UNKNOWN.
reassessment of phase 2 study indication
Phase I Solid Tumors trial by Daiichi Sankyo. Stop reason: OTHER/UNKNOWN.
Clinical investigations have been discontinued and transfer to BMS 3/24/2015
Phase II Stroke trial by Daiichi Sankyo. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Stroke trial by Daiichi Sankyo. Stop reason: OPERATIONAL.
study was stopped for business/administrative reasons and not for patient safety concerns